Debio 025

Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, which could become part of the future standard of care for hepatitis C. Debio 025 has a lower potential for resistance selection. Debiopharm commenced a Phase I study on an Asiatic population.
Debio 025 has been licenced to Novartis for the entire world except Japan.